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who were transplanted at our facility between 2001 and 2005. 30
patients were placed on a thalidomide maintenance program.
Patients received various cytoreductive regimens prior to stem-
cell collection. 27 patients who received thalidomide were in
partial remission prior to ASCT; 3 patients were in complete
remission and none were refractory. Of the 38 patients who did
not receive maintenance 35 were in partial remission, 2 were in
complete remission and 1 was refractory. All patients except 2
received a preparative regimen including melphalan 200 mg per
meter squared. 24 patients received thalidomide maintenance
with 100 mg daily and 6 patients received 50 mg daily. The dose
given depended on prior tolerability of the drug and history.
Thalidomide was started between 120 and 150 days post ASCT.
Patients needed to have an ANC above 1000 and platelets above
100 as well as resolution of transplant related toxicities. 13
patients needed a decrease in thalidomide because of neuropa-
thy. One of these 13 patients also suffered from decreased GI
motility and bezoar.
The average time to progression was 32.5 months in the thalid-
omide group and 19 months in the patients who did not receive the
drug. Patients who received thalidomide after transplant had im-
proved median time to progression (36 months) compared to
patients who did not receive thalidomide (15 months). Low dose
thalidomide maintenance in combination with bisphosphonates
seemed to improve progression free survival in myeloma patients
after stem cell transplantation.
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Background and Rationale
Thalidomide Dexamethasone (Thal Dex) is one of the standard
preparation treatments for auto-transplant in patients with Multi-
ple Myeloma (MM). We evaluated 49 patients with MM to deter-
mine whether outcomes differed between those receiving Thal Dex
and those receiving Vincristine, Doxorubicin, and Dexamethasone
(VAD).
Materials and Methods
A retrospective assessment was performed of MM patients who
were transplanted at Inova Fairfax Hospital from 1997-2005. All
patients received either VAD or Thal Dex as primary therapy and
in preparation for auto-transplant. All patients had Karnofsky per-
formance scores of 80% and all were apheresed using a high
volume technique and ideal body weight for calculations with
G-CSF (G) or GGM-CSF, with goal of 5106/kg CD34 cells. All
patients were given 200 mg/m2 of Melphalan (MEL) over two days
and were treated with growth factor support G beginning day 4
though ANC recovery of 1000. Blood product replacement was
standardized to transfuse for hemoglobin 8 gm/dl or platelet
counts of 10,000/mm3. Viability was performed using ﬂow cy-
tometry and propidium iodide. Continuous variables were analyzed
as means and 95% conﬁdence intervals, but p-values were pro-
duced using a Wilcoxon Rank Sum Test for non-normally distrib-
uted data. Categorical variables were analyzed using a Fisher’s
Exact Test.
Discussion
In MM patients with comparable pretransplant performance sta-
tus being equal, there were no statistical differences in CD34 yield,
cell viability, days of apheresis, platelet transfusions, engraftment,
complications, or mobilization regimen between those receiving
VAD and those receiving Thal Dex. However, patients receiving
Thal Dex appeared to require more RBC blood product support
(p0.03).
Results
Variables/Drug
Group Thal Dex (N11) VAD (N38) p-value
Age (years) 59.8 {53.6, 66.0} 56.5 {52.9, 60.2} 0.38
Days of
apheresis 2.18 {1.46, 2.91} 2.00 {1.68, 2.32} 0.60
CD 34 yield 7.95 {4.05, 11.8} 7.82 {6.34, 9.30} 0.74
Viability Day 1 84.3 {76.8, 91.8} 80.6 {73.2, 88.0} 0.63
Viability Day 2 85.0 {78.3, 91.7} 90.8 {88.1, 93.5} 0.06
Viability Day 3 82.4 {71.8, 93.0} 84.0 {74.7, 93.3} 0.83
Days to ANC
Engraftment 14.1 {13.3, 14.9} 13.7 {13.1, 14.2} 0.36
Days to PLT
Engraftment 18.5 {15.9, 21.2} 19.8 {17.3, 22.3} 0.82
Number of PLT
Transfusions 3.91 {1.61, 6.21} 3.74 {2.61, 4.87} 0.84
Number of RBC
Transfusions 4.54 {3.00, 6.09} 3.00 {2.39, 3.61} 0.03
Mobilization
Regimen (%G) 100 76 0.10
Death <100
days 0 0 1.00
Mucositis II-IV
<30 days 25 13.5 0.36
Sepsis <30 days 16.7 2.7 0.12
Pneumonia <30
days 8.3 2.7 0.40
Karnofsky Score 95.83 94.48 1.00
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Background: The recommended treatment for younger patients
(pts) with newly diagnosed symptomatic MM is ASCT after some
form of cytoreductive therapy. One of the goals of the cytoreductive
therapy is to reduce the tumor bulk, in particular, decrease the plasma
cell bone marrow (BM) inﬁltration to less than 10-30% prior to stem
cell collection. However, the utility of this approach is controversial.
Objective: To evaluate the impact of the degree of plasma cell bone
marrow (BM) inﬁltration on mobilization kinetic and transplant out-
comes. Method: We conducted a retrospective study on all pts with
MM who underwent ASCT at our institution between 1/99 and
12/03. Stem Cell mobilization regimen consisted of the combination
of Cyclophosphomide 1.5-3g/m2, GM-CSF (5mcg/kg) starting on
Day #3 and G-CSF (5mcg/kg) on Day#7 until targeted CD 34 count
achieved. The median age at ASCT was 55 (range 41-73). All pts
received melphalan 200mg/m2 as conditioning regimen. The pts were
grouped according to degree of plasma cell inﬁltration on BM biopsy
performed beforemobilization. Group 1 had plasma cell inﬁltration of
10% (n26), group 2 had 10-29% involvement (n27) and group
3 had 30% plasma cell inﬁltration (n16). Results: Sixty-nine
patients were included in the study; 43 were rapid mobilizers (4
106 CD34 cells/Kg in one single collection), 7 slow mobilizers
(1.5  106 CD34 cells/kg over 4 collections or more) and 19
normal mobilizers (all other patients). The median days of apheresis
was 1 (range 1-6). Ordinal logistic regression model identiﬁed that for
each 10 point (10%) increase in plasma cell BM inﬁltration prior to
mobilization, it is 1.27 times more likely to be in the next slower
mobilization group (p value 0.0449). Age did not inﬂuence the
mobilization kinetic. The median progression-free survival and over-
all survival for the entire cohort were 28.5 and 45months respectively.
There was no relationship found between plasma cell involvement
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